Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Iovance Biotherapeutics ( (IOVA) ).
On June 10, 2025, Jean-Marc Bellemin, the Chief Financial Officer of Iovance Biotherapeutics, announced his resignation effective July 10, 2025, to pursue other opportunities. This departure may impact the company’s financial leadership and strategic direction as it continues to develop cancer immunotherapies.
The most recent analyst rating on (IOVA) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.
Spark’s Take on IOVA Stock
According to Spark, TipRanks’ AI Analyst, IOVA is a Neutral.
Iovance Biotherapeutics shows promising revenue growth and shareholder support but faces profitability and operational challenges. Mixed technical indicators and valuation concerns further affect the score. Positive earnings call highlights are counterbalanced by operational issues.
To see Spark’s full report on IOVA stock, click here.
More about Iovance Biotherapeutics
Iovance Biotherapeutics operates in the biotechnology industry, focusing on the development of novel cancer immunotherapies.
Average Trading Volume: 13,152,863
Technical Sentiment Signal: Sell
Current Market Cap: $748M
For an in-depth examination of IOVA stock, go to TipRanks’ Overview page.